Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
MHY1485
Cat. No.:
OB0225LY-0292
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR and HPLC.
Size:
Product Overview
Description:
MHY1485 is a small molecule inhibitor that specifically targets the mTOR signaling pathway with the potential to regulate cell growth and metabolism.
Synonym:
326914-06-1; 4,6-Dimorpholino-N-(4-nitrophenyl)-1,3,5-triazin-2-amine; 4,6-Dimorpholin-4-yl-N-(4-nitrophenyl)-1,3,5-triazin-2-amine; 4,6-Bis(morpholin-4-yl)-N-(4-nitrophenyl)-1,3,5-triazin-2-amine
CAS No.:
326914-06-1
Compound CID:
2834965
Formula:
C17H21N7O4
Formula Weight:
387.39
Specification
Relative Density:
1.415 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
MHY1485 can be used for metabolic pathway studies.
Library Information
Targets:
PI3K/Akt/mTOR pathway
Receptors:
mTOR
Pathways:
Autophagy; PI3K/Akt/mTOR signaling
Plate Number:
AOCL-4
Plate Location:
g3
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
3.87 mg/mL; 10 mM
Water Max Solubility:
<1 mg/mL (insoluble or slightly soluble)
Ethanol Max Solubility:
<1 mg/mL (insoluble or slightly soluble)
ALogP:
2.653
HBA_Count:
5
HBD_Count:
1
Rotatable Bond:
5
